Visit https://www.nuvaira.com/ for more. is a privately held medical device company that develops minimally invasive products to improve outcomes for patients suffering from obstructive lung diseases by addressing underlying disease pathophysiology. Specifically, Nuvaira has developed a novel, catheter-based system to treat overactive airway nerves, a common disease feature of both COPD and asthma
, in a procedure called Targeted Lung Denervation (TLD). Nuvaira received CE Mark approval for its dNerva® Lung Denervation System in January 2016. dNerva Targeted Lung Denervation is an investigative bronchoscopic procedure that disrupts pulmonary nerve input to the lung to reduce the clinical consequences of neural hyperactivity. Mechanistically similar to anticholinergics (the principal class of drugs for treatment of COPD), the one-time TLD procedure can durably reduce acetylcholine release, and thus has the potential to reduce exacerbation risk, improve symptoms, and stabilize lung function. Nuvaira is currently enrolling participants in the AIRFLOW-3 clinical trial. Patients can visit https://airflowtrial.com/ to learn more and see if they qualify to participate. is headquartered in Minneapolis, Minnesota USA and has more than 70 patents issued and pending worldwide.
